CAMBRIDGE, UK (2019-08-06) – ProteinLogic, the biomarker discovery and exploitation company, is attending the 71st annual scientific meeting & clinical lab Expo of the American Association of Clinical Chemistry (AACC). Dr Nicolas Huber, CEO of ProteinLogic, commented: “The AACC meeting, with its exclusive focus on laboratory diagnostics, is the most prestigious meeting to be attending…
News and Press
ProteinLogic Completes Multi-Site Clinical Study on TB, Reports Results Exceeding WHO Requirements
CAMBRIDGE, UK (2019-08-01) – ProteinLogic, the biomarker discovery and exploitation company, today announces the completion of its multi-site study on the use of its novel diagnostic technology, ImmiPrint®, for the ruling-out of Active Tuberculosis (TB) disease from a blood sample. Previously, the company had shown that its ImmiPrint technology could achieve the requisite clinical accuracy in…
ProteinLogic Appoints Dr Adrian Woolfson as Non-Executive Director
CAMBRIDGE, UK (2019-06-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Adrian Woolfson as Non-Executive Director. Dr Woolfson is the founder of ProteinLogic, having discovered soluble Cluster of Differentiation antigens that underpin ProteinLogic’s platform technology. He is currently serving as Executive Vice President of Research & Development, Sangamo Inc., CA, USA. Dr….
ProteinLogic has patent granted in USA and EU, files 2nd patent Company expands presence in the TB biomarker space
CAMBRIDGE, UK (2019-01-17) ProteinLogic (PL), the biomarker discovery and exploitation company, has received approval for granting of its first patent in biomarkers for the diagnosis of Tuberculosis in the USA and the EU. At the same time, the company has filed a 2nd patent in the same space. This new patent allows the company to…
ProteinLogic Appoints Dr Edward Gibson as Non-Executive Director
CAMBRIDGE, UK (2018-09-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Edward Gibson as Non-Executive Director. Dr Gibson holds a holds a degree in Chemistry from Bristol University, and a PhD in Biochemistry from Oxford University, where he also performed postdoctoral research. Since then, he has held a number of senior leadership…
ProteinLogic Presents at McGill Summer Institute on Advanced TB Diagnostics
CAMBRIDGE, UK (2018-06-25) ProteinLogic (PL), the biomarker discovery and exploitation company, was invited to present its latest findings at the 8th McGill University’s Summer Institute for Advanced TB Diagnostics, held on the 18th-22nd of June 2018, in Montreal, Canada. CEO Nicolas Huber presented PL’s exciting developments in TB diagnosis to participants from the global TB…
ProteinLogic Joins BIVDA
CAMBRIDGE, UK (2018-06-06) – ProteinLogic the biomarker discovery and exploitation company has become an affiliate member of the British In Vitro Diagnostics Association (BIVDA). BIVDA is the national trade association for companies with major involvement and interest in the In Vitro Diagnostics (IVD) industry and has represented manufacturers and distributors of IVD products for over…
ProteinLogic Presents At Bio€quity 2018, Ghent, Belgium
CAMBRIDGE, UK (2018-05-17) – ProteinLogic attended 19th Bio€quity Europe event, held in Ghent, Belgium. Bio€quity Europe pioneered the turf-neutral concept, creating an open door for all members of the financial community and business development and licensing professionals to do business with independently selected presenting companies. ProteinLogic was invited to present to a panel of investors and…
ProteinLogic At BioTrinity 2018, London, UK
CAMBRIDGE, UK (2018-04-26) – ProteinLogic attended BioTrinity 2018, Europe’s leading biopartnering and investment conference. During the event, ProteinLogic delegates took advantage of the partnering environment to provide exposure of our technology, and our validated TB diagnostic to investors and life-sciences key players. The event included panel discussions of significant interest, especially regarding market access globally, the…
ProteinLogic Appoints Darleen Welford as VP of Regulatory Affairs and Quality Assurance
CAMBRIDGE UK (2018- 03- 05) – ProteinLogic, the biomarker discovery and exploitation company has appointed Darleen Welford as VP of Regulatory Affairs and Quality Assurance (RA/QA) to bring valuable global regulatory expertise, and to further the company’s RA strategy. Darleen has over 19 years’ experience in the field of In Vitro Diagnostic Medical Devices and…